82 FR 26933 - Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Secondary Review
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention Federal Register Volume 82, Issue 111 (June 12, 2017)
Centers for Disease Control and Prevention
Federal Register Volume 82, Issue 111 (June 12, 2017)
| Page Range | 26933-26934 | |
| FR Document | 2017-12123 |
[Federal Register Volume 82, Number 111 (Monday, June 12, 2017)] [Notices] [Pages 26933-26934] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-12123] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Secondary Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the secondary review of applications in response to Funding Opportunity Announcements (FOAs), CE17-003, Research Grants for Preventing Violence and Violence Related Injury (R01); and PHS 2016-02 Omnibus Solicitation of the NIH, CDC FDA, and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]). Time and Date: 8:00 a.m.-5:00 p.m., EDT, July 18, 2017 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463. Matters for Discussion: The meeting will include the secondary review, discussion, and evaluation of applications received in response to FOAs ``Research Grants for Preventing Violence and Violence Related Injury (R01)'', CE17-003; and ``PHS 2016-02 Omnibus Solicitation of the NIH, CDC FDA, and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])''. Contact Person for More Information: Gwendolyn H. Cattledge, Ph.D., M.S.E.H., Deputy Associate Director for Science, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway NE., Mailstop F-63, Atlanta, Georgia 30341, Telephone (770) 488-1430. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and [[Page 26934]] Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017-12123 Filed 6-9-17; 8:45 am] BILLING CODE 4163-18-P
![Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices 26933
Leroy A. Richardson, prevention and control; (2) strategies for DEPARTMENT OF HEALTH AND
Chief, Information Collection Review Office, surveillance, prevention, and control of HUMAN SERVICES
Office of Scientific Integrity, Office of the infections, antimicrobial resistance, and
Associate Director for Science, Office of the related events in settings where Centers for Disease Control and
Director, Centers for Disease Control and Prevention
Prevention.
healthcare is provided; and (3) periodic
updating of CDC guidelines and other
[FR Doc. 2017–12060 Filed 6–9–17; 8:45 am] Disease, Disability, and Injury
policy statements regarding prevention
BILLING CODE 4163–18–P
of healthcare-associated infections and Prevention and Control Special
healthcare-related conditions. Emphasis Panel (SEP): Secondary
Review
DEPARTMENT OF HEALTH AND Matters for Discussion: The agenda
HUMAN SERVICES will include updates on CDC’s activities In accordance with Section 10(a)(2) of
for prevention of healthcare associated the Federal Advisory Committee Act
Centers for Disease Control and infections (HAIs), an update on the
Prevention (Pub. L. 92–463), the Centers for Disease
Division of Healthcare Quality Control and Prevention (CDC)
Healthcare Infection Control Practices Promotion’s (DHQP) modeling announces a meeting for the secondary
Advisory Committee (HICPAC) activities, updates on the Guideline for review of applications in response to
Prevention of Infection in Neonatal Funding Opportunity Announcements
In accordance with section 10(a)(2) of Intensive Care Unit (NICU) Patients and (FOAs), CE17–003, Research Grants for
the Federal Advisory Committee Act the Guideline for Prevention of Infection Preventing Violence and Violence
(Pub. L. 92–463), the Centers for Disease in Healthcare Personnel, and updates Related Injury (R01); and PHS 2016–02
Control and Prevention (CDC), National from the following HICPAC workgroups:
Center for Emerging and Zoonotic Omnibus Solicitation of the NIH, CDC
The workgroup on antibiotic FDA, and ACF for Small Business
Infectious Diseases (NCEZID) announces stewardship principles for inclusion
a meeting of the aforementioned Innovation Research Grant Applications
into clinical practice guidelines, the (Parent SBIR [R43/R44]).
committee: workgroup on updating the CDC
Times and Dates: Time and Date: 8:00 a.m.–5:00 p.m.,
recommendation categorization scheme,
9:00 a.m.–5:00 p.m., EDT, July 13, 2017 EDT, July 18, 2017 (Closed).
the workgroup on developing CDC
9:00 a.m.–12:00 p.m., EDT, July 14, 2017 recommendations for products and Place: Teleconference.
Place: Centers for Disease Control and practices, and the National Healthcare Status: The meeting will be closed to
Prevention, Global Communications Safety Network (NHSN) Surveillance the public in accordance with
Center, Building 19, Auditorium B, 1600 Workgroup. provisions set forth in Section
Clifton Road NE., Atlanta, Georgia, 552b(c)(4) and (6), Title 5 U.S.C., and
30329. Agenda items are subject to change as
priorities dictate. the Determination of the Director,
Status: Open to the public, limited
Contact Person for More Information: Management Analysis and Services
only by the space available. Time will
Erin Stone, M.A., HICPAC, Division of Office, CDC, pursuant to Public Law 92–
be available for public comment. The
public is welcome to submit written Healthcare Quality Promotion, NCEZID, 463.
comments in advance of the meeting. CDC, l600 Clifton Road NE., Mailstop Matters for Discussion: The meeting
Comments should be submitted in A–07, Atlanta, Georgia 30329, will include the secondary review,
writing by email to the contact person Telephone (404) 639–4045. Email: discussion, and evaluation of
listed below. The deadline for receipt is hicpac@cdc.gov. applications received in response to
June 30, 2017. All requests must contain FOAs ‘‘Research Grants for Preventing
The Director, Management Analysis
the name, address, and organizational Violence and Violence Related Injury
affiliation of the speaker, as well as the and Services Office, has been delegated
the authority to sign Federal Register (R01)’’, CE17–003; and ‘‘PHS 2016–02
topic being addressed. Written Omnibus Solicitation of the NIH, CDC
comments should not exceed one single- notices pertaining to announcements of
meetings and other committee FDA, and ACF for Small Business
spaced typed page in length and Innovation Research Grant Applications
delivered in 3 minutes or less. Members management activities, for both the
Centers for Disease Control and (Parent SBIR [R43/R44])’’.
of the public who wish to provide
public comments should plan to attend Prevention and the Agency for Toxic Contact Person for More Information:
the public comment session at the start Substances and Disease Registry. Gwendolyn H. Cattledge, Ph.D.,
time listed. Please note that the public M.S.E.H., Deputy Associate Director for
Elaine L. Baker, Science, National Center for Injury
comment period may end before the
time indicated on the agenda, following Director, Management Analysis and Services Prevention and Control, CDC, 4770
Office, Centers for Disease Control and Buford Highway NE., Mailstop F–63,
the last call for comments. Written
Prevention. Atlanta, Georgia 30341, Telephone (770)
comments received in advance of the
[FR Doc. 2017–12122 Filed 6–9–17; 8:45 am] 488–1430.
meeting will be included in the official
record of the meeting. BILLING CODE 4163–18–P
The Director, Management Analysis
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Purpose: The Committee is charged and Services Office, has been delegated
with providing advice and guidance to the authority to sign Federal Register
the Director, Division of Healthcare notices pertaining to announcements of
Quality Promotion (DHQP), the Director, meetings and other committee
National Center for Emerging and management activities, for both the
Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and
the Director, CDC, the Secretary, Health
and Human Services regarding (1) the
practice of healthcare infection
VerDate Sep<11>2014 17:28 Jun 09, 2017 Jkt 241001 PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 E:\FR\FM\12JNN1.SGM 12JNN1](https://thefederalregister.org/doc/82_FR_27044/page/1.svg)
![26934 Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
Prevention and the Agency for Toxic identifies you in the body of your applicable disclosure law. For more
Substances and Disease Registry. comments, that information will be information about FDA’s posting of
posted on https://www.regulations.gov. comments to public dockets, see 80 FR
Elaine L. Baker, • If you want to submit a comment 56469, September 18, 2015, or access
Director, Management Analysis and Services with confidential information that you the information at: https://www.gpo.gov/
Office, Centers for Disease Control and do not wish to be made available to the
Prevention.
fdsys/pkg/FR-2015-09-18/pdf/2015-
public, submit the comment as a 23389.pdf.
[FR Doc. 2017–12123 Filed 6–9–17; 8:45 am]
written/paper submission and in the Docket: For access to the docket to
BILLING CODE 4163–18–P manner detailed (see ‘‘Written/Paper read background documents or the
Submissions’’ and ‘‘Instructions’’). electronic and written/paper comments
Written/Paper Submissions received, go to https://
DEPARTMENT OF HEALTH AND
www.regulations.gov and insert the
HUMAN SERVICES Submit written/paper submissions as docket number, found in brackets in the
follows: heading of this document, into the
Food and Drug Administration • Mail/Hand delivery/Courier (for ‘‘Search’’ box and follow the prompts
[Docket No. FDA–2017–N–0493] written/paper submissions): Division of and/or go to the Division of Dockets
Dockets Management (HFA–305), Food Management, 5630 Fishers Lane, Rm.
Agency Information Collection and Drug Administration, 5630 Fishers 1061, Rockville, MD 20852.
Activities; Proposed Collection; Lane, Rm. 1061, Rockville, MD 20852.
Comment Request; Utilization of • For written/paper comments FOR FURTHER INFORMATION CONTACT: For
Adequate Provision Among Low to submitted to the Division of Dockets copies of the questionnaire: Office of
Non-Internet Users Management, FDA will post your Prescription Drug Promotion Research
comment, as well as any attachments, Team, DTCresearch@fda.hhs.gov. For
AGENCY: Food and Drug Administration, except for information submitted, questions on the PRA: JonnaLynn
HHS. marked and identified, as confidential, Capezzuto, Office of Operations, Food
ACTION: Notice. if submitted as detailed in and Drug Administration, Three White
‘‘Instructions.’’ Flint North, 10A63, 11601 Landsdown
SUMMARY: The Food and Drug Instructions: All submissions received St., North Bethesda, MD 20852, 301–
Administration (FDA or Agency) is must include the Docket No. FDA– 796–3794.
announcing an opportunity for public 2017–N–0493 for ‘‘Utilization of SUPPLEMENTARY INFORMATION: Under the
comment on the proposed collection of Adequate Provision among Low to Non- PRA (44 U.S.C. 3501–3520), Federal
certain information by the Agency. Internet Users.’’ Received comments Agencies must obtain approval from the
Under the Paperwork Reduction Act of will be placed in the docket and, except Office of Management and Budget
1995 (PRA), Federal Agencies are for those submitted as ‘‘Confidential (OMB) for each collection of
required to publish notice in the Submissions,’’ publicly viewable at information they conduct or sponsor.
Federal Register concerning each https://www.regulations.gov or at the ‘‘Collection of information’’ is defined
proposed collection of information and Division of Dockets Management in 44 U.S.C. 3502(3) and 5 CFR
to allow 60 days for public comment in between 9 a.m. and 4 p.m., Monday 1320.3(c) and includes Agency requests
response to the notice. This notice through Friday. or requirements that members of the
solicits comments on research entitled • Confidential Submissions—To public submit reports, keep records, or
‘‘Utilization of Adequate Provision submit a comment with confidential provide information to a third party.
among Low to Non-Internet Users.’’ information that you do not wish to be Section 3506(c)(2)(A) of the PRA (44
DATES: Submit either electronic or made publicly available, submit your U.S.C. 3506(c)(2)(A)) requires Federal
written comments on the collection of comments only as a written/paper Agencies to provide a 60-day notice in
information by August 11, 2017. submission. You should submit two the Federal Register concerning each
ADDRESSES: You may submit comments copies total. One copy will include the proposed collection of information
as follows: information you claim to be confidential before submitting the collection to OMB
with a heading or cover note that states for approval. To comply with this
Electronic Submissions ‘‘THIS DOCUMENT CONTAINS requirement, FDA is publishing notice
Submit electronic comments in the CONFIDENTIAL INFORMATION.’’ The of the proposed collection of
following way: Agency will review this copy, including information set forth in this document.
• Federal eRulemaking Portal: the claimed confidential information, in With respect to the following
https://www.regulations.gov. Follow the its consideration of comments. The collection of information, FDA invites
instructions for submitting comments. second copy, which will have the comments on these topics: (1) Whether
Comments submitted electronically, claimed confidential information the proposed collection of information
including attachments, to https:// redacted/blacked out, will be available is necessary for the proper performance
www.regulations.gov will be posted to for public viewing and posted on of FDA’s functions, including whether
the docket unchanged. Because your https://www.regulations.gov. Submit the information will have practical
comment will be made public, you are both copies to the Division of Dockets utility; (2) the accuracy of FDA’s
solely responsible for ensuring that your Management. If you do not wish your estimate of the burden of the proposed
asabaliauskas on DSKBBXCHB2PROD with NOTICES
comment does not include any name and contact information to be collection of information, including the
confidential information that you or a made publicly available, you can validity of the methodology and
third party may not wish to be posted, provide this information on the cover assumptions used; (3) ways to enhance
such as medical information, your or sheet and not in the body of your the quality, utility, and clarity of the
anyone else’s Social Security number, or comments and you must identify this information to be collected; and (4)
confidential business information, such information as ‘‘confidential.’’ Any ways to minimize the burden of the
as a manufacturing process. Please note information marked as ‘‘confidential’’ collection of information on
that if you include your name, contact will not be disclosed except in respondents, including through the use
information, or other information that accordance with 21 CFR 10.20 and other of automated collection techniques,
VerDate Sep<11>2014 17:28 Jun 09, 2017 Jkt 241001 PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 E:\FR\FM\12JNN1.SGM 12JNN1](https://thefederalregister.org/doc/82_FR_27044/page/2.svg)
Document Created: 2017-06-10 01:40:33
Document Modified: 2017-06-10 01:40:33
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | 8:00 a.m.-5:00 p.m., EDT, July 18, 2017 (Closed). | |
| FR Citation | 82 FR 26933 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR